Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Articles|March 24, 2023
5 Key Sessions, Interviews at 2023 APhA Annual Meeting & Exposition
Author(s)Erin Hunter, Assistant Editor
Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.
Advertisement
The theme of this year’s APhA meeting is “Rise! Advancing in the Face of Adversity.” The gathering will provide pharmacy professionals with the opportunity to learn about innovations in the industry, connect with other pharmacists, and work together to tackle obstacles with ingenuity and creativity.
Stay tuned on PharmacyTimes.com for exclusive session coverage and interviews with experts, including:
- Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, dean and professor at Loma Linda University School of Pharmacy, who will provide an update on the 2023 immunization recommendations and offer insight about the status of COVID-19 vaccines.
- Coverage of a session on pain management that delves into alternative, non-pharmacologic interventions to treat chronic pain and develop appropriate treatment strategies.
- A discussion with Kathryn Marwitz, PharmD, MPH, who will dive into debunking misinformation in the pharmacist’s workplace. She will explore social media, the repercussions of patient wellbeing because of misinformation, and how to help facilitate communication of truthful scientific information.
- Coverage of a session on adult ADHD which will delve into how ADHD affects adult patients, and how pharmacists can create a plan to help patients manage the condition.
- A conversation with Vibhuti Arya, PharmD, MPH, FAPhA, who will discuss drug decriminalization, it’s impact on public health, and how pharmacy professionals can address its stigma with patients.
Stay tuned on
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
Advertisement
Advertisement